<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275351</url>
  </required_header>
  <id_info>
    <org_study_id>SM04554-AGA-02</org_study_id>
    <nct_id>NCT02275351</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samumed LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samumed LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, and efficacy of
      topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with
      Androgenetic Alopecia (AGA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in non-vellus hair count</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in non-vellus hair count over time as compared to Baseline. Non-vellus hair count will be determined by macrophotography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in subject assessment of hair growth and quality</measure>
    <time_frame>Day 45, Day 90</time_frame>
    <description>Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hair growth as assessed by the investigator</measure>
    <time_frame>Day 45, Day 90</time_frame>
    <description>Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of AGA on quality of life</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time as compared to Baseline. The KAP is a 38-question survey completed by each subject that assesses his quality of life in relation to AGA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hair density</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in hair density over time as compared to Baseline. Hair density will be measured using macrophotography.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Active Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.15% solution, applied once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.25% solution, applied once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical vehicle solution, applied once a day for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04554</intervention_name>
    <description>Topical solution, applied once a day</description>
    <arm_group_label>Active Arm 1</arm_group_label>
    <arm_group_label>Active Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical solution, applied once a day</description>
    <arm_group_label>Vehicle Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of AGA

          -  Willing to inform females, with whom they may interact, that they are using a topical
             investigational product and direct contact should be avoided as potential harm to a
             fetus is unknown

          -  Willing to maintain the same hair style as at study start for the duration of the
             study

          -  Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers)
             for the duration of the study. Daily styling products will be allowed (e.g., hair gel,
             mousse, styling spray).

          -  Willing to use a mild non-medicated shampoo and conditioner for the duration of the
             study

          -  Willing to receive a small scalp tattoo

          -  Able to read and understand English

        Exclusion Criteria:

          -  Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia

          -  Scalp hair loss on the treatment area, due to disease, injury, or medical therapy

          -  Males who are sexually active and have a partner who is capable of becoming pregnant,
             neither of whom have had surgery to become sterilized, that are not using an effective
             method of birth control and are not willing to use an effective method of birth
             control during the study treatment period until 90 days post last dose of study
             medication

          -  Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun
             damage, seborrheic dermatitis), cuts and/or abrasions on the scalp or condition (e.g.,
             sunburn, tattoos) on the treatment area that, in the opinion of the Investigator,
             might put the subject at risk or interfere with the study conduct or evaluations

          -  History of surgical correction of hair loss on the scalp

          -  Previous exposure to SM04554

          -  Use of any products or devices purported to promote scalp hair growth (e.g.,
             finasteride or minoxidil) within the 24 weeks prior to study start

          -  Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone
             acetate, cimetidine) within 12 weeks prior to study start

          -  History of hair transplants

          -  Current use of an occlusive wig, hair extensions, or hair weaves

          -  Participation in any other investigational drug or medical device trial, which
             included administration of an investigational study medication or medical device,
             within 30 days or 5 half-lives of the investigational agent, whichever is longer,
             prior to study start

          -  Subjects with a history of clinically significant cardiac arrhythmia as determined by
             the Investigator

          -  Subjects with clinically significant findings from medical history, clinical
             laboratory tests, electrocardiogram (ECG), or vital signs that, in the opinion of the
             Investigator, could interfere with the objectives of the study or put the subject at
             risk

          -  Subjects unwilling to refrain from sperm donation during the study treatment period
             until 90 days post last dose of study medication

          -  Subjects with pregnant partners at study start

          -  Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30
             days prior to study start

          -  Use of medicated shampoo or conditioner within 30 days prior to study start
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Samumed LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alopecia</keyword>
  <keyword>topical</keyword>
  <keyword>Samumed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

